Description

Leukeran Coated Tablets 2 mg. №25 Vial

Ingredients:

Each coated tablet contains 2 mg of chlorambucil as the active ingredient.

Mechanism of Action:

Leukeran, a nitrogen mustard alkylating agent, exerts its cytotoxic effects by interfering with DNA replication and RNA transcription in rapidly dividing cells.

Pharmacological Properties:

The pharmacological properties of Leukeran involve its ability to disrupt the growth and spread of cancer cells by inhibiting key processes involved in cell division.

Indications for Use:

Leukeran is indicated for the treatment of chronic lymphocytic leukemia (CLL), Hodgkin’s disease, and certain types of non-Hodgkin’s lymphomas.

Contraindications:

Leukeran is contraindicated in patients with a history of hypersensitivity to chlorambucil or any of the tablet’s components.

Side Effects:

Common side effects of Leukeran may include nausea, vomiting, diarrhea, and myelosuppression. Patients should be monitored for potential adverse reactions.

Usage Instructions:

The dosage of Leukeran should be individualized based on the patient’s condition and response to treatment. It is important to follow the prescribing physician’s instructions carefully. The tablets should be taken orally with or without food as directed by the physician. Do not crush or chew the tablets.

Benefits Compared to Analogues:

Leukeran has shown efficacy in combination therapy for CLL, leading to improved overall response rates and progression-free survival compared to single-agent therapy.

Suitable Patient Groups:

Leukeran is suitable for adult patients with the specified indications under the supervision of a healthcare provider. Special caution should be exercised when prescribing to elderly patients or those with compromised renal or hepatic function.

Storage Conditions and Shelf Life:

• Leukeran should be stored at room temperature away from moisture and heat.
• Pregnant women should avoid handling Leukeran tablets due to the potential risk of harm to the fetus.

Packaging Description:

Leukeran is available in vials containing 25 coated tablets of 2 mg each.

Clinical Evidence and Proven Effectiveness:

Research published in the Journal of Clinical Oncology has demonstrated the efficacy of Leukeran in combination therapy for CLL, leading to improved overall response rates and progression-free survival compared to single-agent therapy.